Key Revisions Finalized for Federal IDR Processes Under No Surprises Act
The Departments of Health and Human Services, Labor, and Treasury and the Office of Personnel Management released a final rule May 28 to improve the...
The Centers for Medicare & Medicaid Services (CMS) is expanding Medicare coverage for genetic testing through the MolDX program administered by Palmetto GBA.
CMS announced two new local coverage determinations (LCDs) to cover diagnostic tests used to evaluate and manage care for patients suspected of having hereditary transthyretin amyloidosis:
- Genetic Testing for Heritable Thoracic Aortic Disease (L39933)
- Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis (L39935)
The LCDs will take effect Aug. 17 in 23 states.
Source:
https://www.cap.org/advocacy/latest-news-and-practice-data/july-8-2025
Stay Compliant with CMS and the New ABN Requirements
The Centers for Medicare & Medicaid Services (CMS) has issued an updated version of the Advance Beneficiary Notice of Noncoverage (ABN).
Prior Authorization Process Reform in Medicare Advantage Gaining Traction in Congress
The Improving Seniors’ Timely Access to Care Act (S.1816/H.R.3514) is gaining significant bipartisan support in both chambers of Congress.